SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Duramed (DRMD) Synthetic Estrogen Product
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Chisy who wrote (1390)8/10/1999 2:34:00 PM
From: muddphudd  Read Replies (1) of 1837
 
I think I see a similar problem here as the one that Cypress Bioscience is facing now (CYPB). CYPB got a new treatment for Rheumatoid Arthritis (RA) approved by the FDA earlier this year. It is a medical device that removed the harmful antibodies thought to play a role in RA (it is an auto-immune condition). The problem is that they are having a tough time penetrating the rheumatology market. Same for DuraMed. If they can't convince the docs that they should at least try Cenestin then it won't matter if they have the best drug on the market. I have a few friends who are drug reps for Pfizer and Organogenesis. They often mention how difficult it is to get docs to switch to a new med from an old med that they have been prescribing FOR YEARS.
I hope DRMD can overcome this hurdle.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News